Vaccine

Abstract

The present invention relates to the field of bacterial polysaccharide antigen vaccines. In particular, the present invention relates to bacterial polysaccharides conjugated to protein D from H influenzae.

1 - 18 . (Cancelled).  
     
     
         19 . An immunogenic composition comprising a plurality of polysaccharide conjugate antigens consisting of a polysaccharide antigen derived from a pathogenic bacterium conjugated to protein D from  Haemophilus influenzae  or a protein D fragment thereof.  
     
     
         20 . The immunogenic composition as claimed in  claim 19  wherein the polysaccharide antigens are selected from the group consisting of: Vi polysaccharides from  Salmonella typhi , meningococcal polysaccharides, polysaccharides and modified polysaccharides of group B meningococcus, polysaccharides from  Staphylococcus aureus , polysaccharides from  Streptococcus agalactiae , polysaccharides from  Streptococcus pneumoniae , polysaccharides from Mycobacteria, polysaccharide from  Cryptococcus neoformans , lipopolysaccharides of non-typeable  Haemophilus influenzae , capsular polysaccharide from  Haemophilus influenzae  b, lipopolysaccharides of  Moraxella catharralis , lipopolysaccharides of  Shigella sonnei , and lipopeptidophosphogylcan (LPPG) of  Trypanosoma cruzi.    
     
     
         21 . The immunogenic composition as claimed in  claim 20  comprising  Streptococcus pneumoniae  polysaccharide antigens from at least four  Streptococcus pneumoniae  serotypes.  
     
     
         22 . The immunogenic composition of  claim 20  additionally comprising at least one  Streptococcuspneumoniae  protein antigen.  
     
     
         23 . The immunogenic compositions of  claim 22 , wherein the protein antigen is an outer surface protein or a secreted protein of  Streptococcus pneumoniae  or immunologically functional equivalents thereof.  
     
     
         24 . The immunogenic composition of  claim 22 , wherein the protein antigen is a toxin, adhesin or lipoprotein of  Streptococcus pneumoniae  or immunologically functional equivalents thereof.  
     
     
         25 . The immunogenic composition of  claim 22 , wherein the protein antigen, or immunologically functional equivalent thereof, is selected from the group consisting of: pneumolysin, PspA or transmembrane deletion variants thereof, PspC or transmembrane deletion variants thereof, PsaA or transmembrane deletion variants thereof, glyceraldehydes-3-phosphate dehydrogenase, and CbpA or transmembrane deletion variants thereof.  
     
     
         26 . The immunogenic composition of  claim 20 , wherein the polysaccharide antigens conjugated to protein D are derived from a combination of  N. meningitidis  serotypes A, C or Y.  
     
     
         27 . An immunogenic composition comprising conjugated capsular polysaccharides of  Haemophilus influenzae  b, meningococcus C and meningococcus Y, wherein the capsular polysaccharide antigens are conjugated to protein D from  H. influenzae , with the proviso that the capsular polysaccharide from  Haemophilus influenzae  b is conjugated to tetanus toxoid.  
     
     
         28 . An immunogenic composition comprising conjugated capsular polysaccharides of  Streptococcus pneumoniae, Haemophilus influenzae  b, meningococcus C and meningococcus Y, wherein the capsular polysaccharide antigens are conjugated to protein D from  H. influenzae , with the proviso that the capsular polysaccharide from  Haemophilus influenzae  b is conjugated to tetanus toxoid.  
     
     
         29 . An immunogenic composition as claimed in any of the preceding claims additionally comprising an adjuvant.  
     
     
         30 . An immunogenic composition as claimed in claimed  29  wherein the polysaccharide—protein D conjugate antigens are adsorbed onto aluminum phosphate.  
     
     
         31 . An immunogenic composition as claimed in  claim 29  wherein the adjuvant is a preferential inducer of a TH1 response.  
     
     
         32 . An immunogenic composition as claimed in  claim 31 , wherein the adjuvant comprises at least one of the following: 3D-MPL, a saponin immunostimulant, or an immunostimulatory CpG oligonucleotide.  
     
     
         33 . An immunogenic composition as claimed in  claim 19  for use as a medicament.  
     
     
         34 . A vaccine comprising the immunogenic composition of  claim 29 .  
     
     
         35 . A method of producing an immunogenic composition to a plurality of pathogenic bacteria comprising the steps of: 
 isolating a plurality of polysaccharide antigens from said pathogenic bacteria;    activating the polysaccharides;    conjugating the polysaccharides to protein D from  H. influenzae ; and    mixing the conjugated polysaccharides together.    
     
     
         36 . A method of treating a patient suffering from, or susceptible to, infection from a pathogenic bacterium comprising administering an effective amount of an immunogenic composition as claimed in  claim 19.